Home  |  About SITC  |   Twitter  |  LinkedIn  |  YouTube  |  Oncology Tube  |  Sitemap

JITC

The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the Society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy—from basic research to clinical application.

Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for the Journal for Immunotherapy of Cancer, an outlet devoted to and created by today's leaders in the field.

Indexed in PubMed and PubMed Central

Less than a year after its first issue, JITC was accepted to PubMed and PubMed Central! This is an exciting step in the evolution of JITC, as it now offers greater visibility and accessibility to all accepted articles.

Free Publication for SITC Members

As a way to say thank you to the dedicated Society members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, SITC is pleased to offer Society members waived article processing charges for manuscripts accepted in 2015. To take advantage of this member benefit, contact SITC at +1 414-271-2456 or info@sitcancer.org for your member code.

SITC Best Paper Awards

SITC will once again be offering two $1,000 USD awards for the best papers submitted in the Clinical/Translational and Basic Science categories. To be eligible, papers must be published in JITC by August 18, 2015.

2014 SITC Best Paper Awards Announced

Winners were announced at SITC's 29th Annual Meeting Award Ceremony on Saturday, November 8, 2014. Congratulations!

JITC Best Basic Science Paper Award


First Author:

Stefani Spranger, PhD
University of Chicago

"Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment"

JITC Best Clinical Application Paper Award


First Author:

Shailender Bhatia, MD
University of Washington

"Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase I/II study"

Learn more about this year's award-winners' work, including what's next for their research in this Biome exclusive.

Call for Submissions

The journal welcomes submissions in the following areas and other related topics:

  • Basic Tumor Immunology
    Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, other combination treatments with the anti-tumor immune response, and oncolytic viruses

  • Case Reports
    Reports on unusual or unexpected clinical cases that expand the field of general medical knowledge.  Includes information on an unexpected association between diseases or symptoms, an unexpected event in the course of observing or treating a patient, findings that shed new light on the possible pathogenesis of the disease or an adverse effect, unique or rare features of the disease, and/or a unique therapeutic approach

  • Clinical/Translational Cancer Immunotherapy
    First-in-man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcome, combination therapies, and cell therapies

  • Clinical Trials Monitor
    Announcements and updates of cancer immunotherapy clinical trials in progress. Includes perspectives and implications of late stage pivotal clinical trials results and new regulatory approvals. Articles may also focus on other pertinent regulatory issues to help define a road map for navigating the clinical trial landscape

  • Commentary/Editorials
    Reaction to and/or perspectives on significant events in the field in the basic science area. May address a critical challenge, elaborate or extend a conversation of a focal article, provide an application of a theoretical perspective, or shed light on a particular issue in the field

  • Immunotherapy Biomarkers
    Predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies, clinical trial analyses and identification of novel immune biomarkers

  • Reviews
    Fact/data-driven works that cumulate several articles of importance on a particular subject or research area in a review format with the goal of providing the “state of the art” in the field.  Includes recent major advances and discoveries, significant gaps in the research, current debates, and/or ideas of where research might go next

Submit your manuscript.

JITC Editorial Board

The Editorial Board is comprised of internationally recognized thought leaders in the field and experts in their content areas.  They are also members of SITC and deeply committed to advancing the knowledge about, and integration of, cancer immunotherapy research into the clinical setting.

View the full listing of the JITC Editorial Board.



Society for Immunotherapy of Cancer
555 East Wells Street, Suite 1100  |  Milwaukee, WI 53202-3823 USA
Tel: +1 414 271 2456  |  Fax: +1 414 276 3349  |  Email: info@sitcancer.org
About SITC  |  Meetings  |  Membership  |  Patient/Consumer Resources  |  Professional Resources  |  Support SITC
© 2015 Society for Immunotherapy of Cancer. All rights reserved.